|
Indication for OAC
|
Regular medical care
|
Coagulation service
|
|---|
|
Frequency
|
Time in therapeutic range
|
Frequency
|
Time in therapeutic range
|
|---|
|
Atrial fibrillation
|
66.2% (1,332)
|
67.5% (49.3/83.3)
|
61.1% (464)
|
75.0% (61.8/77.3)
|
|
Deep vein thrombosis
|
6.1% (123)
|
65.2% (46.8/75.3)
|
14.2% (108)
|
75.3% (66.1/85.0)
|
|
Peripheral vascular bypass surgery
|
8.0% (160)
|
64.9% (47.1/81.2)
|
2.2% (17)
|
74.9% (61.8/77.3)
|
|
Prosthetic heart valve
|
9.7% (195)
|
42.2% (30.4/68.3)
|
7.4% (56)
|
76.8% (63.0/82.8)
|
|
Pulmonary embolism
|
7.7% (154)
|
66.5% (50.6/82.6)
|
13.3% (101)
|
75.5% (64.7/84.7)
|
|
Others*
|
5.0% (100)
|
70.1% (54.3/82.1)
|
5.0% (38)
|
79.2% (59.8/88.0)
|
- Patients can have more than one indication for oral anticoagulation (OAC) with vitamin K antagonist; indication is described in 2,011 of patients in regular medical care and 760 patients in the coagulation service cohort. In coagulation service patients with pre-treatment in regular medical care, information on regular medical care pre-treatment are described within regular medical care cohort (non-disjunct data). Frequency of indication is depicted as relative and absolute frequency. Time in therapeutic range was calculated in patients with at least 4 months of anticoagulation treatment except self-management patients (1,160 patients in regular medical care and 560 patients in coagulation service, respectively). *e.g., cerebral venous sinus thrombosis, Paget-Schrötter disease.
